Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat switch versus continued PDE-5 inhibitor therapy in pulmonary arterial hypertension
NL-OMON45410Phase 4Completed
- Sponsor
- Bayer
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of riociguat in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Bayer. Primary endpoint: Satisfactory clinical response at Week 24. Started Oct 2017; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON45410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45410.